Evotec SE (NASDAQ:EVO – Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $4.16, but opened at $4.32. Evotec shares last traded at $4.29, with a ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

Despite macroeconomic uncertainty and geopolitical instability, the S&P 500 rallied to new all-time highs in 2024. Unfortunately, there were plenty of stocks that missed out on the bull market rally.

EVT-401 is under clinical development by Evotec and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 69% phase transition success ...

In this article, I’ll be looking once again at German company Evotec (NASDAQ:EVO) (OTCPK:EVOTF) – a business in the drug ...

Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture ...

“We are thrilled to be able to start work on these first projects, leveraging Evotec’s integrated drug discovery and translational platforms and Novo Nordisk’s deep disease understanding,” said Dr ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Evotec SE (NASDAQ: EVO), a leader in drug discovery and development, has presented its financial results for the first nine months of 2024, maintaining its full-year guidance... Investing.com - Evotec ...

LAB eN 2, the drug discovery accelerator launched by Evotec and Novo Nordisk in September 2023, has unveiled its first three projects and launched an expansion featuring five new academic partners.